Determination of immunogenic proteins in biopharmaceuticals by UHPLC-MS amino acid analysis

What is the role of current mass spectrometry in pharmaceutical analysis?

The role of mass spectrometry (MS) has become more important in most application domains in recent years. Pharmaceutical analysis is specific due to its stringent regulation procedures, the need for good laboratory/manufacturing practices, and a large number of routine quality control analyses to be carried out. The role of MS is, therefore, very different throughout the whole drug development cycle. While it dominates within the drug discovery and development phase, in routine quality control, the role of MS is minor and indispensable only for selected applications. Moreover, its role is very different in the case of analysis of small molecule pharmaceuticals and biopharmaceuticals. Our review explains the role of current MS in the analysis of both small-molecule chemical drugs and biopharmaceuticals. Important features of MS-based technologies being implemented, method requirements, and related challenges are discussed. The differences in analytical procedures for small molecule pharmaceuticals and biopharmaceuticals are pointed out. While a single method or a small set of methods is usually sufficient for quality control in the case of small molecule pharmaceuticals and MS is often not indispensable, a large panel of methods including extensive use of MS must be used for quality control of biopharmaceuticals. Finally, expected development and future trends are outlined.

A dimedone-phenylalanine-based fluorescent sensor for the detection of iron (III), copper (II), L-cysteine, and L-tryptophan in solution and pharmaceutical samples

The development of fluorescence molecules for the fast and effective detection of L-tryptophan (L-Trp) has attracted a lot of attention because it is an important amino acid for baby growth, nitrogen equilibrium in adults, improving sleep, and mood regulation. A dimedone-phenylalanine-based chiral sensor (SDPA) was synthesized and exhibited a strong fluorescence quenching by Fe³⁺ and Cu²⁺ in a water/DMSO (3/7) solution with a detection limit of 2.29 × 10^-6 M and 6.37 × 10^-6 M, respectively. The factors affecting fluorescence sensings, such as the pH and competing cations, were studied. The sensor can be reused at least five times after being treated with EDTA. The Job plot, ESI-MS spectra, ¹H NMR spectra, absorbance, and fluorescence titration experiments were investigated to study the mechanism of SDPA-Fe³⁺ and SDPA-Cu²⁺ complexation. The SDPA-Cu²⁺ complex can detect L-tryptophan and L-cysteine at trace levels by turn-on fluorescence with a detection limit of 9.35 × 10^-6 M and 8.86 × 10^-6 M, respectively. Moreover, applying the SDPA-Cu²⁺ complex for quantitative analysis of L-tryptophan in real sleep-improving capsules resulted in good recovery. The L-tryptophan level of the Elining capsule was determined at 190.8 ± 10.5 mg/g (mg L-tryptophan/g medicine), which is close to the announced quantity of 180 mg/g. Besides, the SDPA-Cu²⁺ complex can selectively detect free L-Try molecules and L-Try residues in proteins.

Profiling of Amino Acids in Urine Samples of Patients Suffering from Inflammatory Bowel Disease by Capillary Electrophoresis-Mass Spectrometry

Urine represents a convenient biofluid for metabolomic studies due to its noninvasive collection and richness in metabolites. Here, amino acids are valuable biomarkers for their ability to reflect imbalances of different biochemical pathways. An impact of amino acids on pathology, prognosis and therapy of various diseases, including inflammatory bowel disease (IBD), is therefore the subject of current clinical research. This work is aimed to develop a capillary electrophoresis-tandem mass spectrometry (CE-MS/MS) method for the quantification of the 20 proteinogenic amino acids in human urine samples obtained from patients suffering from IBD and treated with thiopurines. The optimized CE-MS/MS method, with minimum sample preparation (just “dilute and shoot”), exhibited excellent linearity for all the analytes (coefficients of determination were higher than 0.99), with inter-day and intra-day precision yielding relative standard deviations in the range of 0.91–15.12% and with accuracy yielding relative errors in the range of 85.47–112.46%. Total analysis time, an important parameter for the sample throughput demanded in routine practice, was shorter in ca. 17% when compared to established CE-MS methods. Favorable performance of the proposed CE-MS/MS method was also confirmed by the comparison with corresponding ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) method. Consistent data for the investigated amino acid metabolome were obtained using both methods. For the first time, the amino acid profiling by CE-MS approach was applied on the clinical IBD samples. Here, significant differences observed in the concentration levels of some amino acids between IBD patients undergoing thiopurine treatment and healthy volunteers could result from the simultaneous action of the disease and the corresponding therapy. These findings indicate that amino acids analysis could be a valuable tool for the study of mechanism of the IBD treatment by thiopurines.